Hepatitis C virus (HCV) infection is prevalent in patients with kidney disease including transplant candidates and recipients. It is associated with increased morbidity and mortality in end-stage renal disease patients and also increases the risk of allograft rejection and decreases allograft and patient survival post-transplant. Newly developed direct acting antivirals have revolutionized the way HCV is treated. Whether patients are treated before or after kidney transplantation, the cure rates with direct acting antivirals are >90%. Great debate has formed revolving the optimal timing to treat kidney transplant candidates. On the one hand, treatment before transplantation decreases early post-transplant complications related to HCV. On the other, postponing treatment until after transplantation opens the possibility of transplanting a kidney from a HCV positive donor, which is associated with shorter waiting time and improved organ utilization by expanding the organ donor pool. Most patients living in an area where waiting time is reduced by accepting an HCV positive kidney would benefit by the strategy of treatment post-transplantation, but this decision needs to be individualized in a patient-by-patient basis given that there are special circumstances (i.e., severe HCV-related extrahepatic manifestations, availability of live donors, etc.) in which treatment before transplant might be preferred.
INTRODUCTION
Worldwide, it is estimated that chronic Hepatitis C virus (HCV) infection affects 1.0% to 2.4% of the population, 1, 2 with approximately 3 million people infected in the United States. 3 Hepatitis C virus infection is associated with higher incidence of chronic kidney disease (CKD) and more rapid progression to end-stage renal disease (ESRD). 4, 5 Not surprisingly, patients with CKD and ESRD are disproportionately affected by HCV infection. Prevalence rates in dialysis-dependent patients vary greatly worldwide from as low as 3% in some European countries to 68% in Saudi Arabia (in the United States is 7-14%), [6] [7] [8] [9] and prevalence rate in kidney transplant recipients is 2% to 8%. [10] [11] [12] [13] HCV infection in CKD, ESRD, and kidney transplant patients is associated with increased morbidity and mortality. 14 In the post-transplant period, in addition to its hepatic complications (i.e., liver disease progression to cirrhosis and hepatocellular carcinoma), HCV has been associated with increased risk of allograft rejection, chronic allograft nephropathy, new-onset diabetes after transplant (NODAT), cardiovascular disease, de novo or recurrent glomerulonephritis, post-transplant lymphoproliferative disorder and overall lower graft and patient survival. 13, [15] [16] [17] [18] Despite these added risks, kidney transplantation confers better long-term survival in HCV-infected patients compared with those who remain on the waiting list. [19] [20] [21] The survival benefit of kidney transplantation in HCV positive recipients, as compared with remaining on the waiting list, is evident after 6 months post-transplant with a hazard ratio of 0.32 (95% confidence interval, 0.17, 0.62). 20 Hence, the preferred management for ESRD in HCV infected patients is kidney transplantation. However, given its associated increased morbidity and mortality, it is of utmost importance to treat and eradicate HCV infection in this vulnerable population. The optimal timing of treatment (i.e., before or after kidney transplantation) has been a topic of active debate.
The 2008 KDIGO guidelines on HCV recommend considering treatment for all patients on the waiting list for kidney transplantation with interferon (IFN)-based regimens. 9 Since this recommendation was published 2 important developments have taken place. First, is the development of direct acting antivirals (DAAs) a new group of highly effective medications against HCV infection that can be safely used before or after transplantation. Second, is the increased availability of HCV positive organs due to the opioid epidemic in the United States. Therefore, the updated KDIGO guidelines on HCV, 22 currently in draft form open for public comment and anticipated to be released shortly, recommends the use of IFN-free regimens. In terms of timing of treatment, they recommend to individualize the decision depending on donor type, waiting time differences, HCV genotype, and severity of liver disease. The draft form of the KDIGO guidelines on HCV also suggests that, if receiving a HCV positive kidney increases the likelihood of getting transplanted, HCV positive recipients should be treated after transplantation. 22 In this review we will summarize the most important points to guide clinicians and transplant centers to develop a management strategy for their HCVinfected patients on the waitlist.
SAFETY AND EFFICACY OF HCV TREATMENT BEFORE AND AFTER TRANSPLANT
The first consideration when deciding on timing of HCV treatment in CKD patients is the efficacy and safety of available agents. Of particular concern in CKD populations are drugs that are renally cleared, allograft specific side effects (i.e., rejection, graft failure) and drug-drug interaction with immunosuppressive agents.
Prior to the development of DAAs, treatment of HCV infection consisted of IFN or pegylated-IFN (PEG-IFN) with or without ribavirin (RBV). The efficacy of this regimen is suboptimal with sustained virological response (SVR) rates ranging from 33% to 56% in dialysisdependent patients [23] [24] [25] [26] [27] and 13% to 41% in kidney transplant recipients. 28 Sustained virological response rates are comparable with PEG-IFN vs. standard IFN but are somewhat higher when these agents are combined with RBV. More concerning than the relatively low efficacy is the poor tolerability of IFN or RBV-based treatments. In particular, IFN treatment in kidney transplant recipients is associated with allograft rejection and failure and is not recommended following transplantation. 28 In fact, the 2008 KDIGO guidelines on HCV recommend treatment of HCV post-transplant with IFN-based regimens only in the event of an urgent indication such as life-threatening vasculitis or fibrosing cholestatic hepatitis. 9 The draft form of the new KDIGO guidelines on HCV recommends to avoid IFN in kidney transplant patients. 22 RBV is a challenging drug to use in the CKD population because of high rates of hemolytic anemia. 29 Moreover, over 25% of hemodialysis (HD) patients discontinue IFN therapy early due to adverse events. 26, 27 In part due to these issues, only 3.7% of HCV-infected kidney transplant candidates on the waiting list were treated for HCV in the era before the development of DAAs. 30 The recent development of DAAs has revolutionized HCV treatment with SVR rates routinely above 95% in the general population. Earlier DAAs targeted only a specific HCV genotype and were not tested or tolerated in patients with CKD. More recently pan-genotypic DAA regimens that are safe in advanced CKD have been developed. Studies of DAAs in CKD, ESRD and transplant patients lagged behind those of other populations but recent studies of DAAs in patients with CKD stage 4-5 including HD patients have shown SVR rates of 90% to 99% [31] [32] [33] [34] [35] [36] (Table 1) . In kidney transplant patients the SVR rates have been 98% to 100%. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Direct acting antiviral regimens are well tolerated with low rates of adverse events and treatment discontinuation reported both in dialysis-dependent [31] [32] [33] [34] [35] and kidney transplant patients. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] As expected, anemia is more common with regimens that include RBV. 32, 39, 41, 42 An important point to note is that up to 36% of patients require adjustments of calcineurin inhibitor dosing necessitating careful monitoring of drug levels. However, no increased risk of acute rejection has been noted. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] A randomized controlled trial in which patients on the kidney transplant waiting list are randomized to be treated with DAAs either before or after kidney transplantation has not been done to date, and probably will never be done. However, the data available at this point suggests that the safety and efficacy of DAAs is likely similar pre-vs. post-kidney transplant.
BENEFITS OF ACCEPTING A HCV POSITIVE KIDNEY
Hepatitis C virus-infected patients on the kidney transplant waiting list are eligible to receive a kidney from an HCV infected donor. From 2005 through 2014 in the United States, 6546 kidneys from HCV positive deceased donors were authorized to be transplanted, but only 2402 (37%) of those kidneys were transplanted, with the remainder discarded. 48 Indeed, HCV positive kidneys are discarded at 2.9 times the rate of HCV negative kidneys. 49 Ironically, given that the opioid epidemic predominantly affects young people with fewer comorbidities, discarded HCV positive kidneys have better kidney donor profile index scores, 48 and are less likely to be "extended criteria donors," "donor after cardiac death," or have a final creatinine >1.5 mg/dL when compared with non-HCVinfected kidneys. 49 Furthermore, it is unknown how many organs were never procured as a result of HCV infection. Simultaneously, only 29% of HCV infected recipients receive an HCV positive kidney transplant. 49 Therefore, policies leading to increased rates of transplanting HCV positive kidneys to HCV positive recipients would improve organ utilization.
Due to the large supply of HCV positive kidneys, HCV positive recipients willing to accept HCV positive kidney experience dramatic reductions in waiting time that likely results in decreased morbidity and mortality 41, 42, [48] [49] [50] ( Table 2 ). In a study from the US analyzing data reported to United Network for Organ Sharing (UNOS) from 1995 to 2009, HCV positive patients receiving an HCV positive kidney waited an average of 395 fewer days than patients receiving an HCV negative kidney in the same center. 49 More recent single-center studies have shown an even greater reduction in waiting time with the majority of patients receiving an HCV positive kidney within 2 to 3 months; dramatically lower than the average waiting time at their specific transplant centers of 3.5 to 6.0 years. 41, 42, 50 Another advantage is lower costs, mostly due to less time on dialysis. 51 As a result, new strategies to utilize the discarded HCV positive kidneys have been proposed, including transplanting them to recipients with no HCV infection (HCV negative) with prompt treatment with DAAs. Early results of 2 ongoing trials are very promising: although the majority of patients became viremic post-transplant, 100% of them cleared the virus with very good safety profiles of the DAA regimens used. 50, 52 At this point it is advised to only transplant HCV positive kidneys into HCV negative recipients in a clinical trial setting until further data is available. But, if this becomes a common practice in the future, it has the potential to change the major drivers for advocating to treat HCV after transplantation (i.e., organ availability and waiting time advantage). At that point, organ procurement agencies will have to decide how to allocate HCV positive kidneys: would HCV infected patients be offered these organs first? Or, should both HCV positive and HCV negative waitlisted patients have the same access to HCV positive kidneys?
The data summarized in this section originated solely in the United States and might not be generalizable to other parts of the world. One small Italian study from 2001 to 2004 found a decrease in waiting time from 24 to 9 months with the use of HCV positive donor kidneys for HCV positive transplant candidates. 53 Data on discard rates of HCV positive kidneys and waiting time differences from other countries is lacking. In addition, waiting Although decreasing waiting time and the discarding of kidneys from HCV positive donors that would otherwise be suitable for donation are both laudable goals, the principal question is whether accepting an HCV positive kidney confers a survival benefit to HCV positive recipients as compared with remaining on the waiting list for an HCV negative kidney. No study to date has been able to answer this question. The mortality of patients on dialysis remains high (166 per 1000 patient-years 54 ), and HCV infected ESRD patients obtain a survival benefit by receiving a kidney transplant (irrespective if the donor is HCV positive or negative) as compared with remaining on the waiting list. [19] [20] [21] Some studies report higher mortality in HCV positive patients receiving an HCV positive kidney compared with those receiving an HCV negative kidney, but the difference is small (1 and 2% lower survival at 1 and 3 years, respectively), 49 and other studies have found no difference. 55 Furthermore, this data comes from the pre-DAA era, during which few HD and transplant patients were treated for HCV. 30 New studies are needed to evaluate patient and graft survival in the DAA era, where the majority of patients can achieve SVR, to guide decision-making about timing of HCV treatment and transplantation. Nevertheless, the degree of survival benefit likely depends on the amount of waiting time reduction. It is intuitive to hypothesize that if the difference in waiting time is 5 years, likely there is a morbidity and mortality benefit of accepting an HCV positive kidney instead of waiting for an HCV negative kidney. But what if the difference in waiting time is only 6 months (as it might be in some UNOS regions or other countries)?
Would this benefit differ if the 6-month difference changed waiting time from 6 to 5.5 years as compared with 2 to 1.5 years? Would patients living in areas where waiting times are already short benefit from reducing their waiting time even more by accepting a HCV positive kidney? The answers to these important questions remain unknown.
SCENARIOS IN WHICH TREATMENT BEFORE TRANSPLANTATION IS PREFERRED
For the majority of patients living in areas where waiting time can be reduced substantially by receiving an HCV positive kidney, waiting for HCV treatment until after transplantation is likely the best strategy. However, certain individual patient clinical characteristics would require a different strategy determined on a patient-bypatient basis. Several of these specific scenarios are reviewed below and in Table 3 . Importantly, these recommendations can be made because clearance of HCV in treated patients on the waitlist is durable after transplantation.
56,57

Significant extent of liver damage
All HCV-infected patients should undergo assessment of the extent of liver injury as part of the kidney transplant evaluation to identify those patients who would benefit from a simultaneous liver/kidney (SLK) transplant. This can be done by liver biopsy or by noninvasive tests with measurement of either serum liver fibrosis biomarkers or liver stiffness with transient elastography. 58 For those with advanced cirrhosis (Metavir stage F3 or F4), evaluation of portal hypertension is required. Patients with portal pressure >10-12 mmHg or with clinical evidence of decompensated cirrhosis should be evaluated for SLK. Expected waiting time in that center.
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Candidates for SLK transplant should be treated for HCV after transplantation because transplant is the priority in the setting of decompensated liver disease. If the patient is a candidate for kidney-alone transplantation, the decision to treat before or after transplant would focus on the likelihood of liver disease progressing while waiting for transplantation. Unfortunately, no validated scoring system or other method exists to assess this risk. If there is a substantial risk of liver disease progression, then HCV treatment should be started before transplant with the hope to decrease morbidity and mortality associated with liver disease. This approach would also improve organ utilization since it could prevent the patient from requiring a SLK transplant.
Extrahepatic manifestations of HCV
Hepatitis C virus infection can result in extrahepatic manifestations including mixed cryoglobulinemia syndrome (MCS), and lymphoproliferative disorders. 60 The first line treatment for HCV-associated MCS consists of DAA treatment to eradicate the HCV with the addition of immunosuppressive agents such as glucocorticoids, rituximab, or cyclophosphamide, as well as plasmapheresis for severe life-threatening MCS. DAAs are effective in the treatment of MCS with improvement in vasculitis symptoms, cryoglobulin levels, and for those patients with glomerulonephritis, improvement of serum creatinine and proteinuria. 61 Patients with active HCV-associated MCS should undergo treatment before transplantation as they are otherwise not transplant candidates.
Achieving SVR has been associated with regression of lymphoproliferative disorders in more than 75% of cases related to HCV. 62, 63 As a result, treatment of HCV should be prioritized before transplantation in patients with lymphoproliferative disorders due to HCV, who are otherwise not candidates for kidney transplantation until the lymphoproliferative disorder is in remission.
HCV-infected kidney transplant candidates with living donors
When HCV-infected ESRD patients have a potential living donor, the decision to treat before or after transplantation depends on the anticipated timing of the transplant. If the transplant is not imminent, it is reasonable to treat before transplant as treatment times are generally 12 weeks in length with even shorter regimens on the horizon. Because confirmation of SVR12 is a prudent approach, the total delay would be 24 weeks, a time period that likely does not confer unacceptable additional risk to the patient. A critical point to consider in this decision is that the transplant team must be highly confident that the patient will receive a live donation because if the donor is disqualified to donate, and the recipient was already successfully treated for HCV, the patient would have lost a major advantage on the deceased donor list as eligibility to receive an HCV positive kidney would be lost. In this setting, treatment before transplant is safer when the anticipated delay is due to factors in the recipient's management rather than those of the donor. In the event that the transplant is anticipated in fewer than 24 weeks, then the timing of treatment depends on the risk associated with remaining on dialysis for 24 weeks while HCV is treated/monitored for SVR compared with undergoing transplantation with active HCV infection, with potential HCV-related post-transplant complications. This decision requires weighing the potential morbidity, mortality, and decreased quality of life associated with dialysis 54 vs. the risk of allograft rejection, shorter graft survival and other complications associated with HCV infection including de novo or recurrent glomerulonephritis, liver disease progression, NODAT, and cardiovascular disease. 13, [15] [16] [17] [18] It is our opinion that transplantation should not be delayed solely because of HCV treatment, but treatment decisions should be individualized for specific patient situations. [64] [65] [66] Other situations to consider When receiving an HCV positive kidney is not an option, either because of patient preference, transplant center policy, or government regulations (in nations that do not allow the use of HCV positive organs for transplantation), there is no benefit to delaying HCV treatment in the setting of effective regimens for patients with stage 4-5 CKD and ESRD. [31] [32] [33] [34] [35] In these situations, patients should be treated for HCV as soon as possible to prevent the potential HCV complications both before and after transplant.
In parts of the world where DAAs are not available and not likely to be available in the near future, patients should be considered for treatment with IFN-based 
TIMING OF HCV TREATMENT FOLLOWING TRANSPLANTATION
When treatment after transplant is selected, many transplant centers opt to wait 6 months following transplantation before starting HCV treatment. The main advantage of this strategy is fewer dose adjustments of immunosuppressants during the early post-transplant period when the risk of acute rejection is the highest, since 36% of patients treated with DAAs require such changes. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Another advantage of waiting 6 months after transplant is that it allows for determining whether the HCV-infected recipient was super-infected with a second HCV genotype from an HCV positive donor. However, with the expected approval of pangenotypic DAA regimens this issue will become of lesser importance.
However, a 6-month delay in treatment could have unintended negative consequences. HCV infection increases the risk of developing NODAT, which affects 25% of HCV-infected transplant recipients in the firstyear post-transplant, 67 and this increased risk is evident even in the first 6 months post-transplant. 68 Since both NODAT and HCV infection increase morbidity and mortality, it may not be advisable to wait 6 months posttransplant to initiate DAA treatment. Indeed, HCV treatment was successful and well tolerated in studies of DAAs in the early post-transplant period including 2 prospective studies that treated patients starting at 3 months posttransplant. 38, 39, [41] [42] [43] [44] [45] [46] Furthermore, in the THINKER and EXPANDER-1 trials, which are testing the safety and efficacy of transplanting HCV negative recipients with HCV positive kidneys, patients were treated with DAAs in the immediate post-transplant period. 50, 52 The preliminary experience with DAAs in the immediate post-transplant period revealed SVR rates of 100% and few adverse events. Therefore, earlier HCV treatment after transplant may be appropriate.
CONCLUSION
The newly available DAAs and the opioid epidemic present in the United States and other nations are 2 recent factors that have directly affected the approach to kidney transplantation in candidates with HCV infection (Figure   1 ). On the one hand, we have the means to treat an infection associated with increased morbidity and mortality effectively and safely. On the other, the increased availability of HCV positive organs translates into shorter waiting time on the kidney transplant waiting list for HCV-infected kidney transplant candidates. Therefore, most patients would benefit from treatment after kidney transplantation, assuming the patient consents to receive a HCV positive donor kidney and that the HCV positive waiting time is shorter than in the standard list. However, specific clinical instances exist where HCV treatment before transplantation is recommended ( Table 3 ). The risks and benefits of waiting for HCV treatment until after kidney transplantation might not be generalizable to all parts of the world and local data should be reviewed by each transplant center. Lastly, an open and clear discussion between nephrology, hepatology, transplant nephrology, transplant surgery, and infectious disease specialists is extremely important in deciding on the timing of HCV treatment in kidney transplant candidates.
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